ABCC6 and chronic myelogenous leukemia, BCR-ABL1 positive: Here we demonstrate for the first time, that ABCC6 plays a role in the export of nilotinib and dasatinib from CML patient MNCs and that ABCC6 inhibition increases the efficacy of these TKIs.